Tissue pharmacokinetics of DHP107, a novel lipid‐based oral formulation of paclitaxel, in mice and patients by positron emission tomography-Reference-Cited by-同舟云学术

Tissue pharmacokinetics of DHP107, a novel lipid‐based oral formulation of paclitaxel, in mice and patients by positron emission tomography

Published:2021-06-04 Issue:5 Volume:14 Page:1747-1755
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Moon Byung Seok¹,Park Hyun Soo²,Sunwoo Jung³,Lee In‐Hyun⁴,Kim Anhye⁵,Moon Seol Ju⁶,Lee Heechan⁷,Son Min Hee⁴,Kim Su Bin²,Park Sun Mi¹,Woo Sang‐Keun⁸,Jang Jun‐Hee⁴,Kim Bom Sahn¹,Kim Jee Hyun⁹,Kim Sang Eun²¹⁰¹¹,Lee Howard⁷¹⁰¹²¹¹

Affiliation:

1. Department of Nuclear Medicine Ewha Womans University Seoul Hospital Ewha Womans University College of Medicine Seoul Korea

2. Department of Nuclear Medicine Seoul National University Bundang Hospital Seoul National University College of Medicine Seoul Korea

3. Department of Clinical Pharmacology and Therapeutics Asan Medical Center University of Ulsan College of Medicine Seoul Korea

4. Pan‐gyo Research Laboratory Daehwa Pharmaceutical Co. Ltd Seongnam Korea

5. Department of Clinical Pharmacology and Therapeutics CHA Bundang Medical Center CHA University Seongnam Korea

6. Biomedical Research Institute Chonbuk National University Hospital Jeonju Korea

7. Department of Clinical Pharmacology and Therapeutics Seoul National University HospitalSeoul National University College of Medicine Seoul Korea

8. Division of RI‐Convergence Research Korea Institute Radiological and Medical Sciences Seoul Korea

9. Department of Internal Medicine Seoul National University Bundang Hospital Seoul National University College of Medicine Seoul Korea

10. Advanced Institutes of Convergence Technology Suwon Korea

11. Department of Molecular Medicine and Biopharmaceutical Sciences Graduate School of Convergence Science and Technology Seoul National University Seoul Korea

12. Center for Convergence Approaches in Drug Development Seoul National University Seoul Korea

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13003

Reference20 articles.

1. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

2. Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

3. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

4. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel

5. Predicting the Efficacy of an Oral Paclitaxel Formulation (DHP107) Through Modeling and Simulation

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nano delivery system for paclitaxel: Recent advances in cancer theranostics;Colloids and Surfaces B: Biointerfaces;2023-08

2. Oral administration of PET tracers: Current status;Journal of Controlled Release;2023-05

3. In vivo tissue pharmacokinetics of ERBB2‐specific binding oligonucleotide‐based drugs by PET imaging;Clinical and Translational Science;2023-04-20

4. Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective.;European Journal of Pharmaceutical Sciences;2021-12